This market resolves Yes to each country that legalizes the use of one or more psychedelic substances between market creation and market close, including cases in which such use is contingent on prescription by a licensed medical professional.

At the time of market creation, studies on the efficacy of psychedelic substances in mental health treatments are being conducted by various institutes globally. Several countries have shown interest in exploring the therapeutic potential of psychedelics, with promising results emerging in the treatment of addiction, schizophrenia, depression, and other disorders.

Some of the countries listed as options already allow the use of some psychedelics in some or all settings.

For example, Australia has legalized the prescription of MDMA and psylocibin effective Jul 1, 2023. In Germany, ibogaine is legal while other psychedelics remain illegal. Brazil has legalized ayahuasca while psilocybin has never been illegal in the country. These countries resolve Yes if psychedelic substances that were illegal as of market creation become legal before market close.

For any country to resolve Yes a change in law at a national level is required. Legalization at the state or provincial level within federal countries, such as the United States, would not be sufficient to resolve a 'Yes' for that country.